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Abstract
Background: Reactive microglia are associated with b-amyloid (Ab) deposit and clearance in Alzhiemer’s Disease
(AD). Paradoxically, entocranial resident microglia fail to trigger an effective phagocytic response to clear Ab
deposits although they mainly exist in an “activated” state. Oligomeric Ab (oAb), a recent target in the
pathogenesis of AD, can induce more potent neurotoxicity when compared with fibrillar Ab (fAb). However, the
role of the different Ab forms in microglial phagocytosis, induction of inflammation and oxidation, and subsequent
regulation of phagocytic receptor system, remain unclear.
Results: We demonstrated that Ab(1-42) fibrils, not Ab(1-42) oligomers, increased the microglial phagocytosis.
Intriguingly, the pretreatment of microglia with oAb(1-42) not only attenuated fAb(1-42)-triggered classical
phagocytic response to fluorescent microspheres but also significantly inhibited phagocytosis of fluorescent labeled
fAb(1-42). Compared with the fAb(1-42) treatment, the oAb(1-42) treatment resulted in a rapid and transient
increase in interleukin 1b (IL-1b) level and produced higher levels of tumor necrosis factor-a (TNF-a), nitric oxide
(NO), prostaglandin E2 (PGE2) and intracellular superoxide anion (SOA). The further results demonstrated that
microglial phagocytosis was negatively correlated with inflammatory mediators in this process and that the
capacity of phagocytosis in fAb(1-42)-induced microglia was decreased by IL-1b, lippolysaccharide (LPS) and tert-
butyl hydroperoxide (t-BHP). The decreased phagocytosis could be relieved by pyrrolidone dithiocarbamate (PDTC),
a nuclear factor-B (NF-B) inhibitor, and N-acetyl-L-cysteine (NAC), a free radical scavenger. These results suggest
that the oAb-impaired phagocytosis is mediated through inflammation and oxidative stress-mediated mechanism
in microglial cells. Furthermore, oAb(1-42) stimulation reduced the mRNA expression of CD36, integrin b1 (Itgb1),
and Ig receptor FcgRIII, and significantly increased that of formyl peptide receptor 2 (FPR2) and scavenger receptor
class B1 (SRB1), compared with the basal level. Interestingly, the pre-stimulation with oAb(1-42) or the inflammatory
and oxidative milieu (IL-1b, LPS or t-BHP) significantly downregulated the fAb(1-42)-induced mRNA over-expression
of CD36, CD47 and Itgb1 receptors in microglial cells.
Conclusion: These results imply that Ab oligomers induce a potent inflammatory response and subsequently
disturb microglial phagocytosis and clearance of Ab fibrils, thereby contributing to an initial neurodegenerative
characteristic of AD. Antiinflammatory and antioxidative therapies may indeed prove beneficial to delay the
progression of AD.
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Microglial phagocytosis has been proposed as an Ab-
lowering mechanism of Ab immunization in Alzhiemer’s
Disease (AD) [1]. Microglia interact with fibrillar Ab
through the cell surface receptor system [2] that pro-
mote the clearance and phagocytosis of fAb.T h ef u n c -
tional components of the receptor system include the
scavenger receptor CD36, CD47 (integrin-associated
protein), b1 integrin (Itgb1) [2-4], macrophage scavenger
receptor class A (SRA) and class B (SRB) [5], receptor
for advanced glycation end products (RAGE) [6,7], and
the formyl peptide receptor (FPR) [8]. Exogenous micro-
glial lateral ventricle transplantation has been shown to
increase Ab clearance in AD model rats [9]. Bone mar-
row-derived microglia can also efficiently restrict amy-
loid deposits [10]. These findings indicate the potential
of exogenous and healthy microglia for therapeutic
approach to AD. However, an enigma still remains:
Why are those entocranial resident microglia surround-
ing plaques “activated” but unable to trigger an effective
phagocytic response to engulf and degrade fibrillar Ab
deposits in ADż Recent evidence indicates that dysfunc-
tional microglia is associated with aging [11,12]. Human
brains containing high Ab loads show a significantly
higher degree of microglial dystrophy than nondemen-
ted, amyloid-free brains. Also, microglial cell senescence
is exacerbated by amyloid [11,12]. Therefore, microglial
degeneration may affect its phagocytosis and serve as an
important factor in AD pathogenesis.
Abundant proinflammatory cytokines, chemokines,
complement products, and oxygen radicals are presented
in AD brains [13,14]. The binding of Ab peptide to cell
surface receptors induces proinflammatory gene expres-
sion and subsequently cytokines production [15]. Ab
seems to modulate these events all the time and interact
with proinflammatory cytokines in a synergistic manner
[16] to induce neuronal damage via reactive oxygen spe-
cies (ROS)-dependent pathways [17]. ROS scavengers
such as catalase obviously reduce the activation of
nuclear factor kappa-B (NF-B), a transcription factor
mediating immune and inflammatory responses [18], and
subsequently decrease the elevated Ab-induced IL-1b
level [19]. Accordingly, strategies to suppress oxidative
stress and NF-B activation may attenuate neuroinflam-
mation and neuronal damage, which will be beneficial to
AD treatment.
The processing of b-amyloid precursor protein (APP)
by b-a n dg-secretases produces Ab peptides, of which
Ab(1-42) is especially biochemical active for its sponta-
neous proneness to oligomerization and fibrillation.
Soluble Ab oligomers rather than Ab fibrils have been
observed as the primary pathological species at early
time points preceding fibril formation [20]. However,
from APP processing to Ab plaque formation, the speci-
f i cr o l eo fA b oligomers and fibrils in mediating micro-
glial activation is still unclear. Particularly, how do Ab
oligomers induce the generation of oxidative stress,
inflammatory response and subsequently affect phagocy-
tosis of Ab fibrils in microgliaż Thus, the effect of Ab
components at different stages on microglia functions
needs to be clarified so as to produce promising strate-
gies to retard the early AD-related pathological affairs.
Here we investigated the differential effect of Ab(1-42)
oligomers versus fibrils on the viability of microglia, the
expressions of inflammatory mediators, and phagocyto-
sis function in microglia. Particularly, we applied the
central Ab components at the early and terminal stage
(oligomers and fibrils, respectively) combined with some
pharmacological agents to treat microglia in a proper
sequential design, in order to study the role of Ab com-
ponents at different stages in microglial phagocytosis
and cell surface components of the phagocytic receptor
s y s t e m ,i n c l u d i n gC D 3 6 ,C D 4 7 ,i n t e g r i nb1, SRA, SRB1,
RAGE, FPR2, as well as the classical phagocytic recep-
tors, the Ig receptors (FcgRIa n dF c gRIII). We further
gained insights into the impact of anti-inflammation and
anti-oxidation on oligomeric Ab-activated microglial
cells in NF-B signaling.
Results
Effects of oligomeric versus fibrillar Ab(1-42) on microglial
cell viability
Previous studies have demonstrated that oligomeric Ab
(1-42) caused neuronal cells death in vitro [21-23].
However, the effect of oligomeric Ab (oAb)o nm i c r o -
glial cell viability remains unclear. In this study, micro-
glial cells were respectively treated with oAb and
fibrillar Ab(1-42) (fAb)a td o s e so f0 . 2t o1 0 . 0μMf o r
48 h. OAb was shown to be cytotoxic to BV-2 and pri-
mary microglial cells when its dosage was up to 5.0 μM
(Figure 1A). OAb a tad o s eo f1 0 . 0μM respectively
resulted in a 45.7% and 39.8% reduction in the viability
of BV-2 and primary microglial cells (P < 0.001, vs the
control group). There were no significant changes in
microglial cell survival when the dose of oAb was within
the range of 0.2~1.0 μM. In contrast, fAb at doses of 0.2
to 5.0 μM resulted in a 22.0~29.4% increase in the viabi-
lity of BV-2 cells (P < 0.001, vs the control group), and
8.8~19.3% in that of primary microglia (P <0 . 0 5o rP <
0.001,,vs the control group) (Figure 1B), which suggests
fAb at lower doses well maintain the viability of micro-
glial cells. However, fAb at doses of 10.0 μMo rh i g h e r
did not affect the viability of primary microglia and BV-
2 cells (P > 0.05, vs the control groups). These findings
confirm that the non-neuronal toxicity of Ab oligomes
also occurs in microglial cells.
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activity in a dose- and time-dependent manner in
microglial cells
Microglial phagocytosis was monitored by the inges-
tion of fluorescent microspheres. We investigated the
dose and time course of the influence of oligomeric
Ab(1-42) and fibrillar Ab(1-42) on phagocytosis. fAb
(1-42) enhanced microglial phagocytic function in a
dose-dependent manner (Figure 2A, B). Exposure of
BV-2 cells to fAb(1-42) at a dose of 5.0 μMf o r3 0m i n
produced the maximal phagocytic response, in which
the percentage of phagocytosis cells and that of phago-
cytic efficiency were 72.6 ± 4.4% and 255.5 ± 29.9%,
respectively. Those of the control group were 32.3 ±
8.7% and 76.4 ± 21.7%, respectively. However, oAb(1-
42) had no effect on microglial phagocytosis, even at a
high treatment dose of 10.0 μM (Figure 2A, B), indi-
cating that Ab(1-42) fibrils specifically promotes
microglial phagocytosis. Because oAb (1-42) at the
dose of 1.0 μMa n df A b(1-42) at the dose of 5.0 μM
produced the maximal phagocytic response (Figure 2A,
B )a n dt h e yw e r en o tc y t o t o x i ct om i c r o g l i a lc e l l s( F i g -
ure 1A, B), oAb(1-42) at 1.0 μMa n df A b(1-42) at 5.0
μM were applied to the following time course study of
microglial phagocytosis, respectively. As shown in Fig-
ure 2C, oAb(1-42)-treated microglial cells demon-
strated an initial, slight and transient phagocytic
response to microspheres, which then declined over
time (3~12 h) (P <0 . 0 5vs oAb treated for 30 min).
Interestingly, the elevated phagocytic response trig-
gered by fAb(1-42) occurred early after 30 min of
incubation and kept at a high level for 3~6 h (P <
0.001, compared with the oAb-treated groups) (Figure
2C) which slowly declined at 12 h over time (P <0 . 0 5 ,
fAb treatment for 12 h vs for 30 min). Exposure of the
primary microglia to Ab(1-42) induced a phagocytic
response of similar magnitude (Figure 2D). These
results suggest that microglial cells exhibit a distinct
phagocytic response to two conformations of Ab(1-42).
Differential impact of oligomeric versus fibrillar Ab(1-42)
on the expressions of inflammatory mediators in
microglial cells
The current study also investigated the differential
effects of oligomeric versus fibrillar Ab (1-42) on IL-1b,
TNF-a,N O ,a n dP G E 2 in microglial cells. OAb(1-42)
treatment resulted in a rapid and transient increase in
IL-1b level (Figure 3B), while fAb(1-42)-treated micro-
glial cells released the inflammatory mediators in a slow
a n ds t e p - b y - s t e pm a n n e r( F i g u r e3 D ,F ,H ) .I L - 1 b in
oAb-treated cells peaked at 3 h and declined from 3
through 24 h. In fAb-treated cells, IL-1b peaked at 6 h,
slowly declined and kept at a level from 12 through 24
h. These distinct expression patterns over time resulted
in significantly higher IL-1b level in Ab oligomers-trea-
ted cells than in fibrils-treated cells at the early stage
(Figure 3A). Also, in the dose-dependent response
study, oAb treatment produced higher levels of TNF-a,
NO, and PGE2 when compared with those of fAb treat-
ment (Figure 3C, E, G). In addition, the exposure of
microglial cells to oAb(1-42) produced the maximal
response of TNF-a,P G E 2 and nitrite release at 24 h,
while the maximal response of IL-1b appeared at 3 h
(Figure 3B, D, F, H), supporting the notion that IL-1b is
a key proinflammatory cytokine at the early stage of
glial activation. Exposure of the primary microglia to
two conformations of Ab(1-42) induced an inflamma-
tory response of similar magnitude (data not shown).
Taken together, these results prove the important role
of Ab oligomers in the proinflammatory response of
microglia at the early AD stage, which is distinct from
that of Ab fibrils.
Figure 1 Effects of oligomeric and fibrillar Ab(1-42) on microglial cell viability. Primary microglia and BV-2 cells were treated with
oligomeric and fibrillar Ab(1-42) (0~10 μM) for 48 h. The cell viability was assessed by MTT reduction assay. Values are expressed as mean ± S.E.
(n = 5/group).
#P < 0.05,
###P < 0.001, compared with those of the control. **P < 0.01, ***P < 0.001, compared with those of oligomeric Ab.
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microglial phagocytosis
To mimic and investigate the roles of Ab components at
the early and terminal stages (oligomers and fibrils,
respectively) in microglial phagocytic function, we used a
design of a proper sequential-treated manner, that is,
microglial cells were pre-stimulated with oAb(1-42) (1.0
μM) for 6 h or 12 h, then followed by the addition of fAb
(1-42) (5.0 μM) before a 30 min incubation with micro-
spheres. Intriguingly, the pretreatment of microglia with
oligomeric Ab(1-42) suppressed fAb(1-42)-triggered pha-
gocytosis. Microglial cells treated with fAb(1-42) alone
uptook more Nile red fluorescent microspheres (Figure
4A 1st column). For BV-2 cells, the percentage of phago-
cytic cells induced by the pretreatment of oAb(1-42) for
6ha n d1 2hf o l l o w e db yf A b(1-42) treatment was
~21.5% and ~28.3% lower than that by fAb(1-42) alone,
respectively, (Figure 4B) (P < 0.001). Similarly, this effect
occurred in primary microglia (Figure 4C). The
percentage of phagocytic cells induced by the pretreat-
ment of oAb(1-42) for 6 h and 12 h followed by fAb(1-
42) treatment was ~27.1% and ~36.1% lower than that by
fAb(1-42) alone, respectively, (P < 0.001).
Since phagocytosis of fAb is central to the role of acti-
vated microglia in AD, we further tested the effect of
oAb-prestimulated microglia on the phagocytic response
to fAb itself. oAb(1-42)-stimulated and -unstimulated
microglia with fluorescent labeled fAb were incubated
for 30 min, and cell-associated fluorescence intensity
was measured (Figure 4D-F). Cells pre-stimulated with
oAb(1-42) (1.0 μM), compared with unstimulated cells,
showed a respective decrease in uptaking of labeled fAb
(53.6% for 3 h and 78.2% for 12 h) (P< 0.001) (Figure
4D, F). Moreover, the inhibition of oAb(1-42) on micro-
glial internalizating fAb displayed a time-dependent
effect (P< 0.05) (Figure 4F). The simultaneous view of
t h ee n t i r ec e l l( x-y, x-z and x-z plane) showed fluores-
cent labeled fAb localizing in the cytoplasm. (Figure 4E)
Figure 2 Effects of oligomeric versus fibrillar Ab(1-42) on phagocytic function of microglial cells. (A) Dose dependence of phagocytosis
stimulated by oAb(1-42) and fAb(1-42). BV-2 cells were incubated with the indicated Ab(1-42) (0.2~10 μM) for 30 min before being exposed to
microspheres for an additional 30 min; (B) The number of microspheres taken up per BV-2 cell with or without oAb(1-42) or fAb(1-42) treatment;
(C) Time course of phagocytosis stimulated by oAb (1-42) or fAb(1-42) in microglial cell. BV-2 cells were preincubated with oAb(1-42) (1.0 μM) or
fAb(1-42) (5.0 μM) for 30 min, 3 h, 6 h,12 h before the addition of microspheres for 30 min. (D) Phagocytosis stimulated by oAb(1-42) or fAb(1-
42) in primary microglia. Cells were incubated with the oAb(1-42) (1.0 μM) or fAb(1-42) (5.0 μM) for 30 min before the addition of microspheres.
Each value is expressed as mean ± S.E. of three independent experiments. ***P < 0.001, compared with the oAb-treated groups.
#P < 0.05,
compared with the 30 min treated groups.
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Page 4 of 17Figure 3 Time course and dose response of inflammatory mediators induced by two types of Ab(1-42) in microglial cells.B V - 2c e l l s
were stimulated with two types of Ab(1-42) (1.0 μM) for 1, 2, 3, 6, 12, 24 h. Or cells were stimulated with the Ab(1-42) (0.2~10 μM) for indicated
time (TNF-a, NO and PGE2 for 24 h, or IL-1b for 3 h), then the supernatant was collected for ELISA, EIA or Griess analysis, respectively. Values are
shown as mean ± S.E. **P < 0.01 or ***P < 0.001, oAb versus fAb groups.
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Page 5 of 17Figure 4 oAb(1-42) inhibits fAb(1-42)-stimulated microglial phagocytosis. BV-2 cells or primary microglia induced by oAb(1-42) (1.0 μM), fAb
(1-42) (5.0 μM) alone or pretreatment of oAb(1-42) for 6 h or 12 h followed by fAb(1-42) treatment for 30 min. Fluorescent microspheres (red)
were then added for 30 min. Cells were fixed with 4% PFA and stained with alexa488-conjugated phalloidin to visualize F-actin (green). The
nucleus was visualized with DAPI (blue). (A) Fluorescent images of the distinct microglial phagocytosis. Scale bar = 40 μm. (B, C) Quantification
of Ab-mediated microglial phagocytosis. Data are presented as mean ± S.E. ***P < 0.001, compared with the control.
##P < 0.01,
###P < 0.001,
compared with fAb(1-42) alone. (D-F) Fluorescent labeled fAb(1-42) internalization in microglia. Cells were pre-stimulated without or with oAb(1-
42) (1.0 μM) for 3 h or for 12 h, then incubated with Hilyte-488 labeled fAb(1-42) (5.0 μM) for 30 min, and treated cells were fixed with 4% PFA
and scanned under confocal microscope. Confocal images of microglial cells ingesting green Hilyte-488 labeled fAb were shown in the x-y plane
(D left). Overlays of phase-contrast and confocal images were shown in D right. Scale bars = 25 μm. (E) z-axis scans of cuts through the cells. (F)
Quantification of internalized fluorescent fAb in microglial cells. Values were expressed as mean fluorescence intensity (arbitrary units) of
internalized fAb per cell. Data are presented as mean ± S.E. ***P < 0.001, compared with the unstimulated control group.
#P < 0.05, between 3 h
and 12 h of oAb stimulation.
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of Ab, oligomers, can impair the microglial phagocytic
function, and may subsequently impact the capacity of
microglia to clear terminal fibrils Ab or tissue debris in
the brain.
Oligomeric Ab(1-42) attenuated fAb-stimulated
phagocytosis, which was correlated with the elevated
inflammatory mediators
Basing on the above observations, we further inquired
whether the severe proinflammatory response triggered
by Ab oligomers was correlated with the suppressed pha-
gocytic response mediated by fAb in microglia and
designed the following experiment. Microglia were pre-
treated with oAb(1-42) at a range of concentrations
(0.2~5.0 μM) for 12 h. Cultured supernatants were col-
lected and assayed for inflammatory mediators including
IL-1b,T N F - a,N Oa n dP G E 2. The bottomed cells were
further treated with fibrillar Ab(1-42) (5.0 μM) for 30
min and then incubated with fluoresent microsphere.
Pearson test of correlation analysis revealed that there
was a distinct negative correlation between the oAb(1-
42)-pretreated fAb-stimulated microglial phagocytosis
and the inflammatory mediators (R
2 = 0.58~0.64, P <
0.001) (Figure 5), indicating that there was a probable
causality between the oAb-suppressed fAb-stimulated
phagocytosis and the inflammatory response in microglia.
Two types of Ab(1-42) elicited the intracellular level of
superoxide anion (SOA) in microglial cells: effects of NAC
and PDTC
It has been reported that fibrillar Ab(1-42) was able to
trigger the production of superoxide anion-derived ROS
in microglia [24]. We also tested whether oligomeric Ab
(1-42) elicited intracellular ROS generation in microglia.
In an initial time-dependent response study, the treat-
ment of BV-2 microglial cells with oAb(1-42) produced
the maximal response for SOA at 12 h (data not
shown). Similar to a positive model treated with a
strong oxidant, t-BHP (Figure 6A (c)), the treatment
with oAb(1-42) or fAb(1-42) also indicated clear NBT
positive cells (containing blue formazan particles) (Fig-
ure 6A (d, g)). NBT reduction quantified assay revealed
that the production ofS O Ai n d u c e db yo A b (1-42) at
1.0 μM was ~20% higher than that by fAb(1-42) even at
5.0 μM( F i g u r e6 B )( P < 0.01). In addition, as expected,
the treatment with pyrrolidone dithiocarbamate (PDTC),
an u c l e a rf a c t o r - B( N F - B) inhibitor, or N-acetyl-L-
cysteine (NAC), a free radical scavenger, markedly
inhibited blue formazan particles formation and the pro-
duction of SOA in BV-2 cells (Figure 6A (e, f, h, i) and
6B). The inhibitory efficiency of PDTC (20 μM) was
45%, whereas NAC (5.0 mM) resulted in a 68% reduc-
tion in the production of SOA in oAb(1-42)-induced
microglia. These results support that oxidative stress not
only occurs in Ab oligomers-induced microglia but is
more intensive than that induced by Ab fibrils, and that
anti-inflammatory and anti-oxidative treatments may
relieve this process.
PDTC or NAC rescues oligomeric Ab-elicited phagocytosis
impairment in the inflammatory and oxidative milieu
We further confirmed our hypothesis that oligomeric
Ab-elicited pro-inflammatory molecules and oxidative
environments impair the capacity of microglial cells to
phagocytose. Microglia were treated with IL-1b and LPS
to induce a proinflammatory environment. IL-1b, LPS
and an oxidant (t-BHP) were tested for their effects on
fAb-stimulated microglial phagocytosis and uptaking of
fluorescent labeled fAb. Also, anti-inflammatory agent
and antioxidant, PDTC and NAC, were tested for their
capacity to regulate microglial phagocytosis. As shown
in Figure 7A-a, when microglial cells were exposed to
IL-1b, LPS or t-BHP before fAb stimulation, the capa-
city of microglial phagocytic response was distinctly sup-
pressed (Figure 7A-a). The percentage of phagocytic
cells pretreated with IL-1b, LPS, t-BHP or oligomeric
Ab decreased to near 50%, 48%, 66%, 44% of the induc-
tion by fAb alone, respectively (Figure 7A-a). In con-
trast, the pretreatment of cells with PDTC or NAC
relieved IL-1b, LPS, t-BHP or Ab oligomers-impaired
phagocytosis (Figure 7A-b, c). Phagocytosis changed
Figure 5 Correlations between inflammatory mediators and
the phagocytic response induced by oAb in fAb-stimulated
microglial phagocytosis. Primary microglia were pretreated with or
without oAb(1-42) (0.2, 1.0, 5.0 μM) for 12 h. The supernatant was
collected to determine the levels of IL-1b, TNF-a, PGE2 and NO by
ELISA, EIA and Griess analysis, respectively. On the phagocytosis
assay, the cells were then treated with fAb(1-42) (5.0 μM) for 30 min
and incubated with fluorescent microspheres for another 30 min.
Phagocytosis of the fluorescent microspheres was quantified as
percent of phagocytic cells. Levels of IL-1b, TNF-a, PGE2 and NO
were expressed as relative folds normalized to those of the control.
Data are presented as the mean ± S.E. Pearson test was applied for
the partial correlation analyses, P < 0.001.
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matory revulsants alone (Figure 7A-a). Meanwhile,
PDTC and NAC had no affect on microglial phagocyto-
sis when added alone (Figure 7A-a).
Stimulation of microglial cells with IL-1b, LPS or t-
BHP significantly reduced phagocytosis of fluorescence
labeled fAb to 18%, 26% and 30% of that of unstimu-
lated cells, respectively (P < 0.001) (Figure 7B, C). Inter-
estingly, as expected, the pretreatment of cells with
PDTC markedly relieved IL-1b, LPS, t-BHP or Ab
oligomers-impaired phagocytosis (P < 0.05) (Figure 7C).
NAC pretreatment also rescued t-BHP-impaired phago-
cytosis of fAb (P < 0.05) (Figure 7C). Similar results
were obtained with NAC counteracting IL-1b, LPS or
Ab oligomers-impaired phagocytosis, but differences
were not statistically found (Figure 7C). Neither PDTC
nor NAC treatment alone had affect on microglial pha-
gocytosis (data not shown).
Collectively, these findings further support that Ab
oligomers-induced proinflammatory mediators and oxi-
dative milieu negatively regulate microglial phagocytic
function.
Oligomeric Ab, the inflammatory and oxidative milieu
regulate gene expressions of Ab-related cell surface
receptors in microglial cells
In order to explore why oAb attenuated the fAb-
induced microglial phagocytic function, we investigated
how oAb affected specifically the Ab-related microglial
cell surface receptor system, including CD36, CD47, b1
integrin (Itgb1), SRA, SRB1, RAGE, FPR2, as well as the
classical phagocytic receptors, the Ig receptors (FcRgI
and FcgRIII). As shown in Figure 8, induction of micro-
glial cells with fAb (5.0 μM) for 30 min showed signifi-
cantly increased mRNA expression of CD36 (4.2-fold
increase; P< 0.001), CD47 (2.9-fold increase; P< 0.001),
integrin b1( I t g b 1 )( 5 . 0 - f o l di n c r e a s e ;P< 0.001), SRA
(2.8-fold increase; P< 0.01), FcgRIII (1.0-fold increase; P
<0.05), when compared with the basal level (Figure 8A-
D, I), while fAb did not change the mRNA expression
of SRB1, RAGE, FPR2, FcgR I receptors in microglial
cells. Interestingly, the pre-stimulation of oAb (1.0 or
5.0 μM) for 12 h significantly downregulated the mRNA
expression of CD36 (3.7-fold decrease for oAb at 1.0
μM, 4.1-fold decrease for oAb at 5.0 μM; P< 0.001),
CD47 (2.2-fold decrease for oAb at 1.0 μM, 2.4-fold
decrease for oAb at 5.0 μM; P< 0.001), Itgb1 (4.2-fold
decrease for oAb at 1.0 μM, 4.8-fold decrease for oAb at
5.0 μM; P< 0.001), as well as FcgR III (1.1-fold decrease
for oAb at 5.0 μM; P< 0.01) in microglial cells, com-
pared with fAb alone induction (Figure 8A-D, I). Simi-
larly, in the inflammatory and oxidative milieu, the pre-
stimulation of microglial cells with IL-1b, LPS or t-BHP
also decreased the fAb-induced mRNA expression of
CD36, CD47 and Itgb1 receptors (Figure 8A-C), in
which the mRNA expressed change was 1.8- to 5.0-fold
lower in the pre-stimulated group than that in the fAb
alone group (P< 0.001). Moreover, IL-1b pre-stimulation
decreased SRA (2.1-fold decrease; P< 0.05), FcgRI( 7 9 %
decrease; P< 0.05) and FcgRIII (1.6-fold decrease; P
<0.05) mRNA over-expression in fAb-induced microglial
cells (Figure 8D, H, I). In contrast, the stimulation of
microglial cells with oAb (5.0 μM) for 12 h resulted in a
reduced mRNA expression of CD36 (36% decrease;
Figure 6 Ab induced the intracellular level of superoxide anion
(SOA) in microglial cells: effects of NAC and PDTC. Nitro blue
tetrazolium (NBT) to formazan by superoxide anion (O2
-) was used
to measure the production of SOA. (A) BV-2 cells were pretreated
with NAC (5 mM) or PDTC (20 μM) for 1 h and then stimulated with
oligomeric Ab(1-42) (1.0 μM) or fibrillar Ab(1-42) (5.0 μM) for 12 h.
Treatment of cells with t-BHP (100 μM) alone for 1 h was as a
positive model control. Then NBT was incubated for a further 45
min and was fixed with methanol. The cells containing blue
formazan particles (NBT-positive cells) were visualized under the
microscope. (a): Blank (without NBT incubation); (b): Drug-free
groups; (c): t-BHP alone; (d): oAb alone; (e): NAC+oAb; (f): PDTC
+oAb; (g): fAb alone; (h): NAC+fAb; (i): PDTC+fAb. Scale bar = 50
μm. (B) NBT depositing inside the cells were dissolved with
solubilization solution and the superoxide anion levels were
quantified by the absorbance measured on a microplate reader at
630 nm. Each value is expressed as mean ± S.E.
###P < 0.001,
compared with the drug-free group. **P < 0.01, compared between
groups.
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Page 8 of 17Figure 7 Effects of IL-1b, LPS and t-BHP on the phagocytic response of microglial cells: regulation of PDTC and NAC. BV-2 cells were
pretreated with PDTC (20 μM) or NAC (5.0 mM) alone or with IL-1b (20 ng/ml) for 18 h or LPS (1.0 μg/ml) and oAb(1-42) (1.0 μM) for 12 h or t-
BHP (100 μM) for 1 h. On the day of phagocytosis assay, the cells were treated with fAb(1-42) (5.0 μM) for 30 min and incubated with
fluorescent microspheres for another 30 min (A) or incubated alone with Hilyte-488 labeled fAb(1-42) (5.0 μM) (B-C). Phagocytosis of the
microspheres was quantified as percent of phagocytic cells. (B) Confocal images of microglial cells ingesting green Hilyte-488 labeled fAb.
Overlays of phase-contrast and confocal images were also shown in D right. Scale bars = 25 μm. (C) Quantification of internalized fluorescent fAb
per cell. Values were expressed as mean fluorescence intensity (arbitrary units). Data are expressed as mean ± S.E. from the three independent
experiments. *P < 0.05, **P < 0.01 or ***P < 0.001 compared with the unstimulated control;
#P < 0.05,
##P < 0.01 compared with the drug (PDTC
or NAC)-free group.
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Page 9 of 17P< 0.05), Itgb1 (54% decrease; P< 0.05), FcgRIII (35%
decrease; P< 0.05) (Figure 8A, C, I), but a significant
increased mRNA expression of FPR2 (2.0-fold increase;
P< 0.05) and SRB1 (1.4-fold increase; P< 0.01) (Figure
8E, G) compared with the basal level. However, oAb
stimulation did not change the mRNA expression levels
of CD47, SRA, RAGE, FcgRI( P > 0.05) (Figure 8B, D,
F, H).
These data indicate that microglia, when early exposed
in the oligomeric Ab or proinflammatory cytokines and
oxidative milieu, have decreased the expression of Ab-
related cell surface receptors, and thereby may have
Figure 8 Ab-related cell surface receptors phenotype changes in microglial cells. BV-2 cells were pre-stimulated with oAb(1-42) (0, 1.0 and
5.0 μM) for 12 h or IL-1b (20 ng/ml) for 18 h or LPS (1.0 μg/ml) and or t-BHP (100 μM) for 1 h, then followed by an addition of incubation with
fAb(1-42) (5.0 μM) for 30 min. Total RNA was extracted, and mRNA expression of Ab-related microglial cell surface receptors including CD36,
CD47, integrin b1 (Itgb1), SRA, SRB1, RAGE, FPR2, FcgR I and FcgRIII, were analyzed by real-time PCR(A-I). All gene expressions were normalized to
GAPDH level. The level of control expression was fixed at 1.0. Data were expressed as relative folds compared to control. Values correspond to
mean ± S.E (n = 3). *P < 0.05, **P < 0.01 or ***P < 0.001 compared with the control;
#P < 0.05,
##P < 0.01 or
###P < 0.001, compared with the fAb
(1-42) alone.
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quently clear Ab.
Role of NF-B signaling in the expression of inflammatory
mediators in oAb-stimulated microglial cells
NF-B is an important upstream modulator of proinfla-
matory cytokine and iNOS expression. The involvement
of NF-B in PDTC and NAC-induced suppression of
the production of cytokines, PGE2 and NO was further
examined. As shown in Figure 9A-D, both PDTC and
NAC dramatically decreased the oAb-induced levels of
TNF-a, IL-1b,P G E 2 and nitrite. The ratio of nucleus to
cytosol in NF-B p65 protein, which reflected the level
of NF-B activation, was next examined by Western
blot. In an initial time-dependent response study, the
treatment of BV-2 cells with oAb(1-42) produced the
maximal response of NF-B activation at the time-win-
dow of 30~60 min (data not shown). The rapid oAb(1-
42)-induced increase in the nuclear level of NF-Bp 6 5
was dramatically blockedb yP D T Ca n dN A C( F i g u r e
9E). Quantification of the protein revealed that PDTC
and NAC reduced the ratio of nucleus to cytosol in NF-
B p65 protein by 63.2% and 69.6%, respectively (Figure
9E). These results suggest that NF-Bi sa ni m p o r t a n t
moleculer target that determines the anti-inflammatory
and anti-oxidative activity in oligomeric Ab(1-42)-stimu-
lated microglia.
Discussion
The elucidation of the mechanism by which microglial
phagocytosis is regulated, may help identify the etiology
of Ab desposit and therapeutic targets in aggregation-
prone protein-associated neurodegenerative diseases
such as Alzheimer’s disease. The present study reports
an important and exciting finding that extracellular oli-
gomeric Ab(1-42) suppresses the phagocytic function of
microglia triggered by fibrillar Ab. Our findings support
the hypothesis that microglial dysregulation by
Figure 9 Role of NF-B signaling in the expression of inflammatory mediators in oAb-stimulated microglial cells. (A-D) BV-2 cells were
incubated with oligomeric Ab(1-42) (1.0 μM) in the presence or absence of NAC (5.0 mM) or PDTC (20 μM). After 24 h (TNF-a, NO and PGE2)o r
3 h (IL-1b), the supernatant was collected for ELISA, EIA or Griess analysis. Values correspond to mean ± S.E. (n = 4). **P < 0.01. (E) Images and
quantification data of Western blot showing NF-Bp65 protein. Whole cells and nuclear extracts were prepared after pretreatment of BV-2 cells
with NAC (5.0 mM) or PDTC (20 μM) for 1 h before being stimulated with oAb(1-42) (1.0 μM) for 1 h. Cytosol NF-Bp65 was used as a protein
loading for nucleus p65. Ratio of nucleus p65 to cytocol represented the level of activation of NF-B signaling. Representative of images
revealed the effects of NAC and PDTC on the activition of NF-B. Data were expressed as relative folds compared to control. Values correspond
to mean ± S.E (n = 3). *P < 0.05, **P < 0.01.
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Page 11 of 17oligomeric Ab-elicited proinflammatory and oxidative
stress milieu hampers clearance of fibrillar Ab deposits,
thereby leading to an initial neurodegenerative process
characteristic of AD.
Oligomeric Ab plays a critical role in the pathogenesis
of AD. It is believed to contribute to early impairment
of cognitive functions such as learning and memory
[20,25]. In neuronal cells, it inhibits neuronal viability
10-fold more than fibrillar Ab [21]. In microglial cells,
the current findings reveal that oligomeric Ab (≥ 5.0
μM) is more cytotoxic than fibrillar Ab, suggesting that
Ab oligomers play a critical role in non-neuronal toxi-
city, whereby may lead to glial dysfunction.
Both pro-inflammatory cytokines and oxidative damage
are observed early in the progression of AD [14,26] and
can be detected prior to fibrillar Ab deposition in AD
brain [27]. Microglial activation can also be detected in
vivo in around 50% of patients with mild cognitive impair-
ment (MCI) [28], suggesting microglial activation is an
early affair that involves progressive damage to immune
system of AD patients. Our present data illustrate the phe-
notypic complexity of reactive microglia. Microglial cells
treated with the two conformations of Ab showed differ-
ent profile changes of morphology and inflammatory med-
iators, including IL-1b,T N F - a,N Oa n dP G E 2.T h eA b-
elicited microglial inflammatory responses were character-
ized by a conformation dependent manner. These results
are in accordance with the works of Heuschling and col-
leagues [29,30]. They further demonstrated that the for-
mylpeptide receptor 2 (FPR2) might mediate oAb
signaling and activate c-Jun and NF-B pathway, which is
also consistent with our current data that oAb significantly
upregulated the mRNA expression of FPR2, as well as our
recent report [23] that Ab oligomers can trigger a potent
inflammatory response in microglia through NF-Ba n d
JNK signaling. However, compared with their studies, our
current data clearly displayed that the kinetics’ profiles of
time course and dose response of inflammatory mediators
induced by the two forms of Ab in microglial cells. Ab oli-
gomers resulted in a rapid and transient increase in IL-1b
level. Compared with Ab fibrils, they produced higher
levels of TNF-a,N O ,P G E 2 and intracellular superoxide
anion (SOA). In contrast, a higher concentration and a
longer stimulating time were required for Ab fibrils to
induce microglial activation. Taken together, our present
findings highlight the viewpoint that, at the early stage of
AD, small diffusible oligomers activate microglia, leading
to a more potent induction of inflammation, whereas
fibrillar Ab or plaques sustain the chronic inflammation at
the terminal stage of AD pathogenesis. More importantly,
our findings also reveal that the time course response of
inflammatory mediators in microglia is correlated with the
oAb-impaired microglial phagocytosis stimulated by fibril-
lar Ab.
Phagocytosis, a macrophage function critical for the
uptake and degradation of infectious agents and senes-
cent cells, contributes to the immune and inflammatory
response and performs homeostatic activity in the nor-
mal CNS [31]. Microglia are competent phagocytes and
are efficient in phagocytic uptake of amyloid aggregates
[1,32,33] and senile plaques themselves [34] when exam-
ined in vitro. However, the limited clearance of dysfunc-
tion of microglia is characteristic of several
neurodegenerative diseases [31]. In AD patients, the
phagocytic function of peripheral blood mononuclear
cells has been found to be impaired [35], suggesting that
phagocytic function is also defective in AD.
The present study finds that an early stage component
of Ab, oligomers, is able to impair microglial phagocytic
function and subsequently disturbs the capacity of term-
inal Ab fibrils clearance. Its intriguing findings elucidate
the mechanisms through which oAb works: (1) oAb sti-
mulation downregulates the mRNA expressions of pha-
gocytosing fAb-related receptors such as CD36, integrin
b1, as well as the classical phagocytic receptors, the Ig
receptor (FcgRIII), whereas oAb upregulates the expres-
sion of cell surface receptor genes (such as FPR2) which
can induce a potent microglial proinflammatory
response; (2) the prestimulation of oAb or the inflam-
matory and oxidative milieu (IL-1b, LPS or t-BHP) sig-
nificantly attenuates the fAb-induced mRNA over-
expression of CD36, CD47 and Itgb1 receptors. There-
fore, these findings firstly provide a probable explanation
for why “activated” microglia surrounding plaques lose
their capacity to phagocytose Ab deposits effectively
during the terminal stage of AD brain. Furthermore, our
observation also raises an intriguing question whether
the initial microglial dysfunction induced by Ab oligo-
mers results in a decline in microglial-mediated clear-
ance of tissue debris and microbes, e.g., viruses, bacteria,
fungi, thereby, at the terminal stage of AD, increasing
the risk of encephalic infectious disease, e.g.,
encephalitis.
It has been reported that microglia internalize oAb
through a nonsaturable, fluid phase macropinocytic
mechanism that is distinct from receptor-mediated
endocytosis [36], whereas microglia interact with fAb
through a characterized Ab cell surface receptor com-
plex comprising the B-class scavenger receptor CD36,
a6b1 integrin, and CD47 [3]. In the present study, the
fluorescent microsphere was used as a marker of fluid
phase phagocytosis. We focused not only on the changes
of microglial phagocytic function after the inducement
with different Ab forms (fAb and oAb)i nap r o p e r
order, but also on the uptaking of fAb itself by micro-
glial cells. Our present data reveal that both oAb and
the inflammatory and oxidative milieu (IL-1b,L P So rt -
BHP) significantly attenuated the fAb-induced over-
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for fluorescent microsphere itself, microglial phagocyto-
sis, distinct from the internalization pathways of Ab,
may work through the mechanisms mediated by the
classical phagocytic receptors, the Ig receptors (FcRgI
and FcgRIII) or complement receptors [3].
The “inflammation hypothesis” stresses that hyperac-
tive microglia are the primary cause of AD-associated
neurotoxicity. In contrast, we propose that AD is caused
not only by hyperactive but also by dysfunctional micro-
glia. Microglial cells generate potentially damaging cyto-
kines, nitric oxide, oxygen free radicals, and arachidonic
acid derivatives, which could be mediators of the so-
called secondary damage [37]. Dysfunctional microglia
also show a significant reduction in the expression of
their Ab-binding receptors and Ab-degrading enzymes,
but maintain their ability to produce proinflammatory
cytokines in AD [38,39]. These cytokines may in turn
act in an autocrine manner and promote Ab production
by stimulating b-a n dg-secretases and/or reduce Ab
clearance by reducing expression of Ab-binding recep-
tors and Ab-degrading enzymes [38,39]. Therefore,
together with our present results, we propose that, in a
pathological condition like AD, oligomeric Ab firstly
triggers a rapid and potent inflammation and subse-
quently fibrillar Ab sustains a chronic inflammatory
environment, which suppresses the activation of phago-
cytic machinery, thereby affecting the ability of microglia
to handle potentially toxic compounds, inhibiting clear-
ance of fAb and plaques, inducing a secondary immune
response, and in turn aggravating brain inflammation.
Antiinflammatory and antioxidative therapy can restore
the functions of microglia, promote their capacity to
clear Ab, and decrease the production proinflammatory
mediators, which may indeed be very helpful to delay
the progression of AD.
A previous study reports that Ab(1-42) fibrillization is
a controlling factor in potentiating phagocytosis [40],
which is attenuated by proinflammatory cytokines [41],
and anti-inflammatory mediators, e.g., IL-4 treated
microglia, enhancing the uptake and degradation of Ab
(1-42) [38]. In this study, our results firstly reveal that
microglial phagocytosis was negatively correlated with
oligomeric Ab-induced inflammatory mediators and
ROS. IL-1b, LPS and t-BHP all decreased the phagocy-
tosis of fAb induced-microglia, which could be relieved
by a nuclear factor-B( N F - B) inhibitor (PDTC), as
well as a free radical scavenger (NAC), suggesting that
impaired phagocytosis by oAb is mediated through NF-
B signaling dependent-inflammation and oxidative
stress mechanism in microglial cells. Thereby, our
results support a model in which the induction of oligo-
meric Ab in microglia promotes oxidative damage and
autocrine proinflammatory cytokine, which contributes
to glial dysregulation and suppresses activation of the
phagocytic machinery at the early stage of AD.
ROS is critical for inflammatory gene expression,
including iNOS, in glial cells [42]. Microglia as a robust
source of ROS increase oxidative stress and contribute
to their dysregulation in AD. In this study, the elevated
phagocytic response triggered by fAb(1-42) occurred
early after initial 30 min of incubation and kept at a
high level for 3~6 h, but slowly declined at 12 h over
time, which also indicates that the elevated ROS
induced by fAb itself may counteract with or negatively
regulate the effect of fAb-elicited phagocytosis. In addi-
tion, the pretreatment of PDTC or NAC mostly blocked
the relocation of NF-B and production of proinflam-
matory cytokines, whereas the same treatment did not
restore the full capacity of phagocytic activity, suggesting
that there may be other pathways involved in the pro-
cess. Together with our current results, therefore, it is
likely that there is a functionally relevant crosstalk
between those different inflammatory events, e.g., secre-
tion of ROS, cytokines, and phagocytosis.
Our findings illustrate that the exposure of microglial
cells to oAb(1-42) produces the maximal response of
TNF-a,P G E 2, and nitrite release at 24 h but that of IL-
1b at 3 h, which supports that IL-1b is an immediate-
response molecule and key immunoregulator at an early
AD stage [43-45]. And the microglial proinflammatory
response in AD may begin before the appearance of pla-
ques in response to oligomeric Ab. The intervention to
prevent microglia activation should commence long
before the appearance of Ab deposits.
Conclusions
The present study demonstrates that Ab oligomers
induce a potent inflammatory response, and subse-
quently disturb microglial phagocytic function preceding
Ab fibrils formation at an early AD stage. This provides
a strong support for a novel view that b-amyloid confor-
mation as an important determinant factor encourages
sequential and progressive damage to the brain’s
immune system at different stages of AD pathogenesis.
The present study also supports that anti-inflammatory
and anti-oxidative therapies may facilitate the recovery
of phagocytosis, the clearance of tissue debris and
microbes, and the removal of fibrillar Ab, and eventually
ameliorate the pathologies of AD brain.
Materials and methods
Reagents
Dulbecco’s modified Eagel’s medium (DMEM), DMEM-
F12, Hanks’ balanced salt solution (HBSS), and fetal
bovine serum (FBS) were obtained from Gibco (Grand
Island, NY); phenol red-free F12 medium from Promo-
Cell (Heidelberg, Germany); and 3-(4, 5-dimethylthiazol-
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Page 13 of 172-yl)-2, 5-diphenyl tetrazolium bromide (MTT), LPS
(from Escherichia coli serotype O111: B4), tert-butyl
hydroperoxide (t-BHP), N-Acetyl-L-cysteine (NAC),
nitroblue tetrazolium (NBT), and hexafluoroisopropanal
(HFIP) from Sigma-Aldrich (St. Louis, MO). Ab(1-42)
peptide was purchased from Quality Controlled Bio-
chemicals, Inc. (QCB, Hopkinton, MA); Lyophilized
HilyteFluor™488 labeled Ab(1-42) peptide was provided
by AnaSpec (Freemont, CA, USA). NF-B inhibitor, pyr-
rolidone dithiocarbamate (PDTC) from Calbiochem (La
Jolla, CA, USA); IL-1b from R & D Systems (Minneapo-
lis, MN); and Nile red fluorospheres and AlexaFluor488-
phalloidin from Molecular Probes (Eugene, OR). Pri-
mary rabbit ployclonal antibody to mouse NF-Bp 6 5
was from Cell signaling (Berverly, MA); 4’,6-diamidine-
2’-phenylindole, dihydrochloride(DAPI), and Wester-
nblot Chemiluminescent Detection System (LumiGLO
system) from KPL (Gaithersburg, MD); TNF-a and IL-
1b ELISA kits from BioSource (Camarillo, CA); PGE2
EIA kit from Cayman (Ann Arbor, MI); TriPure Isola-
tion Reagent and FastStart Universal SYBR Green Mas-
ter (ROX) from Roche Diagnostics GmbH (Mannheim,
Germany); and RevertAid™ F i r s tS t r a n dc D N AS y n t h -
esis Kit from Fermentas (Shenzhen, China).
Cells culture
BV-2 cells culture
The immortalized Murine BV-2 microglial cells were
maintained in Dulbucco’s modified Eagle medium
(DMEM) supplemented with 5% FBS, 100 units/ml peni-
cillin, and 100 μg/ml streptomycin, and were kept at 37°
C in humidified 5% CO2/95% air. The cells were pas-
saged every three days when growing up to 75%
confluence.
Primary microglia culture
Microglia were derived from postnatal day 1 (P1) mouse
brains (C57BL/6). Briefly, meninges-free cortices from
P1 mice were isolated and trypsinized. Cells were plated
onto tissue culture plastic in DMEM-F12 with L-gluta-
mine containing 10% FBS and fed every three days.
After 14 d, the cultures were shaken vigorously (120
min; 260 r.p.m. on a rotary shaker) to remove microglia.
Preparation of Ab(1-42)
Ab(1-42) was prepared as previously described [21,46].
Briefly, lyophilized Ab(1-42) peptide was initially mono-
merized by dissolving it to a final concentration of 1
mM in 100% hexafluoroisopropanal (HFIP) and sepa-
rated into liquots in sterile microcentrifuge tubes. Then
HFIP was evaporated under vacuum in a SpeedVac, and
the peptide film was stored dessicated at -20°C until
use. For the oligomers assembly, the peptide film was
resuspended in dimethylsulfoxide (DMSO) to 5 mM
with water bash ultrasonic for 10 min, then diluted to a
final concentration of 100 μM in phenol red-free F-12
media, and incubated at 4°C for 24 h. To induce fibril
formation, Ab(1-42) was resuspended in sterile MinQ
H2O and incubated for 1 week at 37°C.
Cell viability Assay–MTT assay
MTT is converted in living cells to formazan, which has
a specific absorption maximum. Cells were treated with
Ab(1-42) for indicated time periods and were further
incubated for 4 h after the culture medium was changed
to a medium containing 0.5 mg/ml MTT. Then, they
were added with solubilization solution (10% SDS, 5%
isopropanol in 0.012 M HCl) and incubated at 37°C in
humidified 5% CO2/95% air for overnight. The absor-
bance of the supernatant was measured at 570 nm on
an automated microtiter plate reader. Data were
expressed as the mean percentage of viable cell versus
control.
Phagocytosis assay
Microglial cells were collected and 1 × 10
5 cells were
plated in 24-well plates overnight. The medium was
changed to serum-free DMEM, and 3 h later, the cells
were incubated in the presence or absence of the revul-
sants (IL-1b, LPS, oAb(1-42) or t-BHP) with or without
inhibitors (PDTC or NAC) for indicated time periods.
The fluorescent microspheres, as a marker of fluid
phase phagocytosis, were then added to the treated cells
for 30 min after having been washed in PBS containing
0.1% BSA. Cells were then fixed with 4% paraformalde-
hyde, and three random fields of cells (>100 cells) were
counted under an inverted fluorescent microscope.
Phagocytic efficiency was determined by referring to
Koenigsknecht et al. [3]. Briefly, the phagocytic effi-
ciency was based on a weighted average of ingested
microspheres per cell. The number of cells containing
microspheres, the number of microspheres per cell, and
the total number of cells were counted respectively.
Phagocytic efficiency(%) = (1 × X1+2 × X2+3 × X3....+n
×X n)/the total number of cells × 100%. Xn represents
the number of cells containing n microspheres (n =1 ,2 ,
3, ..., up to a maximum of 6 points for more than 5
microspheres ingested per cell).
Phalloidin staining
The treated cells were rinsed with PBS before being
fixed in 4% paraformaldehyde (PFA) and washed again
in PBS. The cells were then incubated at room tempera-
ture with 0.1% Triton X-100 buffer for 5 min and
washed again in PBS. AlexaFluor488 phalloidin (1:50
diluted in PBS) was added to the coverslips and incu-
b a t e da tr o o mt e m p e r a t u r ep r o t e c t e df r o ml i g h tf o r2 0
min. Finally, coverslips were then incubated with DAPI
(1:1000) for double staining. The coverslips were
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Fluor488-labeled phalloidin was viewed under an
inverted fluorescent microscope.
Fluorescence labeled fAb(1-42) phagocytosis assay
HilyteFluor™488 labeled Ab(1-42) was aggregated
according to the above fibril-forming condition. Primary
microglia or BV-2 cells were plated at a density of 1 ×
10
5 cells/well of a 24-well plate, then were pre-stimu-
lated without or with oAb(1-42) (1.0 μM )f o r3ho r1 2
h, LPS (1.0 μg/ml) for 12 h, t-BHP (100 μM) for 1 h
and IL-1b (20 ng/ml) for 18 h. Stimulated or unstimu-
lated cells were incubated with Hilyte-488 labeled fAb
(1-42) for 30 min at 37°C. Cells were washed and fixed
in 4% PFA. Evaluation of Hilyte-488 labeled fAb(1-42)
phagocytosis in microglia was performed using a confo-
cal microscope (Leica TCS SP5). A photomultiplier
module was used to combine confocal with phase-con-
trast images to provide simultaneous views of the fluor-
escent fAb and the entire cell to distinguish between
phagocytosed fluorescent fAb and fAb adhered to cell
surface. We counted intracellular fluorescent fAb in
three different experiments and analyzed 50 cells for
each experiment. Data acquirement and analysis were
performed with Leica Microsystems software (LAS AF
Lite Version:1.8.1 build 1390).
Measurement of TNF-a, IL-1b, PGE2 and nitrite levels
Microglial cells were stimulated with oligomeric and
fibrillar Ab(1-42) (1.0 μM )f o r1 ,2 ,3 ,6 ,1 2 ,a n d2 4h .
Or cells were stimulated with that of Ab(1-42) (0.2~10
μM) for indicated time (TNF-a, NO and PGE2 for 24 h,
or IL-1b for 3 h). The supernatants were collected and
stored at -80°C until assays for TNF-a,I L - 1 b and PGE2
were performed. TNF-a,I L - 1 b and PGE2 levels were
detected by mouse TNF-a,I L - 1 b ELISA kits and PGE2
EIA kit according to the procedures provided by the
manufacturers. Accumulated nitrite (NaNO2)a c c u m u l a -
tion in the medium was used as an indicator of NO pro-
duction as previously described [47]. The isolated
supernatants were mixed with an equal volume of Greiss
reagent (1% sulfanilamide, 0.1% naphthylethylenedia-
mine dihydrochloride, and 2% phosphoric acid) and
incubated at room temperature for 15 min. NaNO2 was
used to generate a standard curve, and nitrite produc-
tion was determined by measuring optical density at 540
nm. In the above studies with drugs (including PDTC
and NAC), care was taken to ensure that cell viability
was not altered under the concentrations of inhibitors
used.
Modified NBT assay for superoxide anion (SOA)
A modified assay for the intracellular conversion of
nitroblue tetrazolium (NBT) to formazan by superoxide
anion (O2
-) was used to measure the production of reac-
tive oxygen species [48,49]. In brief, 0.1% NBT was
added to the media at the end of the treatment periods.
As negative controls, BV-2 microglial cells were pre-
treated with 5.0 mM NAC 1 h prior to oligomeric or
fibrillar Ab(1-42) treatment. As a positive control, BV-2
cells were treated with 100 μMt - B H Pf o r6 0m i n
[50,51]. After incubation for 45 min at 37°C, the treated
cells were washed twice with warm PBS, then once with
methanol, and air-dried. The NBT deposited inside the
cells was then dissolved with 240 μlo f2Mp o t a s s i u m
hydroxide (KOH) and 280 μl of dimethylsulfoxide
(DMSO) with gentle shaking for 10 min at room tem-
perature. The dissolved NBT solution was then trans-
ferred to a 96-well plate and absorbance was read on a
microplate reader at 630 nm. Meanwhile, the cells were
allowed to adhere to glass cover slips placed in a 6-well
flat culture plate. After similar treatments, NBT incuba-
tion, washing and fixing with methanol were carried
out. The cells containing blue formazan particles (NBT-
positive cells) were pictured under a microscope.
Quantitative real-time PCR
Total RNA was extracted from the treated mouse BV-2
microglial cells using a commercially available assay
(TriPure Isolation Reagent, Roche) according to the
manufacturer’s protocol. First-strand cDNA was synthe-
sized with the use of 1 μg of total RNA (RevertAid™
First Strand cDNA Synthesis Kit, Fermentas). The quan-
titative PCR was performed with Applied Biosystems
7500 Real-Time PCR System (Applied Biosystems, Fos-
ter City, CA, USA) using SYBR Green to detect the
amplification products. Reactions were as follows: 50°C
for 2 minutes, 95°C for 10 minutes, and then 40 cycles
of 95°C for 15 seconds followed by 60°C for 1 minute.
Relative quantification of mRNA expression was calcu-
lated by the comparative cycle threshold (Ct) method
after the target genes levels were normalized to expres-
sion of GAPDH housekeeping control gene for each
sample. The fold difference in gene expression between
treated groups was calculated as follows: fold difference
=2
-ddCt, where ddCt = (Ct-target -C t - GAPDH)treated sample
-( C t - target -C t - GAPDH)control sample.D e s i g n e dp r i m e r s
sequences [see Additional file 1, Table S1] were as fol-
lows: GAPDH, CD36, CD47, integrin b1 (Itgb1), scaven-
ger receptor A (SRA), scavenger receptor B1(SRB1),
RAGE, FPR2, FcgR I and FcgRIII.
Nuclear extract
The treated cells were first resuspended with cold hypo-
tonic buffer A [10 mM HEPES (pH 7.9), 10 mM KCl,
0 . 1m ME D T A ,0 . 1m ME G T A ,1m Md i t h i o t h r e i t o l ,
and 0.5 mM PMSF], followed by vigorous vortex for 15
s before standing at 4°C for 10 min and incubated for
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The cytoplasmic protein was contained in the superna-
tant following centrifugation (6,000 × g,4 ° C ,1 0m i n ) .
The pelleted nuclei were resuspended in cold buffer B
[20 mM HEPES (pH 7.9), 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol, and 1 mM PMSF] and incubated for 20
min on ice, and nuclear lysates were then centrifuged at
14,000 × g at 4°C for 5 min. Supernatants containing
the solubilized nuclear proteins were stored at -80°C for
NF-B assay.
Western blot
The treated cells were washed with ice-cold PBS and
then were incubated for 20 min with lysis buffer con-
taining 10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM
Na4P2O7,2m MN a 3VO4, 0.1% SDS, 0.5% (w/v) sodium
deoxycholate, 1% Triton-X 100, 1 mM PMSF, 60 μg/ml
aprotinin, 10 μg/ml leupeptin, and 1 μg/ml pepstatin.
Then the cells lysates were centrifuged at 12000 × g for
10 min. Nuclear and cytoplasmic extracts were sepa-
rated by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to PVDF
membranes. The membranes were probed with NF-B
p65 subunits antibody (1:750) to determine the effi-
ciency of nucleocytoplasmic separation. Quantification
of the band density was determined by densitometric
analysis.
Statistical Analysis
Data were shown by the means ± S.E. of at least three
independent experiments. Statistical differences between
values were determined by ANOVA followed by Tukey
post hoc test, the partial correlation analyses by Pearson
test. Significance level was set at P < 0.05.
Additional material
Additional file 1: Primers used for real-time PCR
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